Valiant Laboratories
Valiant Laboratories Share Price Chart
Valiant Laboratories last traded at ₹119.90 (2026-10-13). Over the past month the stock moved -3.9%, three months the stock moved +52.3%, year the stock moved +37.9%. Its closing range over 52 weeks is ₹51.79 – ₹127.80, with the latest close 6.2% below the high.
Closing prices up to 2026-10-13.
About Valiant Laboratories
Incorporated in 1980, Valiant Laboratories Ltd manufactures and deals in Pharmaceuticals and speciality chemicals[1]
Business Overview:[1][2] VLL is in the active pharmaceutical ingredient manufacturing business. It manufactures finished dosage forms of paracetamol API viz. Tablets, Capsules, and Other medications. Paracetamol API is a key ingredient used to treat a variety of conditions including Headache, Arthritis, Muscle Aches, Toothache, Backache, Cold, and Fever
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Valiant Laboratories reported sales of ₹115.00 crore (+144.7%) and net profit of ₹21.00 crore (+950.0%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 115.00 | 29.00 | 25.00 | 21.00 | 3.88 |
| Mar 2026 | 92.00 | 5.00 | 5.00 | 2.00 | 0.32 |
| Dec 2025 | 52.00 | -1.00 | -1.70 | -7.00 | -1.30 |
| Sep 2025 | 46.00 | 0.00 | 0.20 | 0.00 | 0.04 |
| Jun 2025 | 47.00 | 2.00 | 5.00 | 2.00 | 0.34 |
| Mar 2025 | 58.00 | 4.00 | 7.00 | 1.00 | 0.13 |
| Dec 2024 | 35.00 | 1.00 | 1.80 | 2.00 | 0.43 |
| Sep 2024 | 21.00 | -7.00 | -31.00 | -5.00 | -0.87 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -65.0% | -14.6% | +87.1% | +147.4% | +119.0% | +48.6% | +58.6% | +144.7% |
| Operating profit growth | – | – | – | – | – | -200.0% | +25.0% | +1350.0% |
| Net profit growth | -600.0% | – | – | – | – | -450.0% | +100.0% | +950.0% |
| EPS growth | -557.9% | – | – | – | – | -402.3% | +146.2% | +1041.2% |
| OPM % | -31.0% | 1.8% | 7.0% | 5.0% | 0.2% | -1.7% | 5.0% | 25.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Valiant Laboratories reported sales of ₹237.00 crore (+78.2%) and net profit of ₹-3.00 crore, compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 237.00 | 6.00 | 3.00 | -3.00 | -0.60 |
| Mar 2025 | 133.00 | -5.00 | -4.00 | -2.00 | -0.41 |
| Mar 2024 | 182.00 | -8.00 | -5.00 | 0.00 | 0.06 |
| Mar 2023 | 334.00 | 35.00 | 11.00 | 29.00 | 7.13 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Sales growth | -45.5% | -26.9% | +78.2% |
| Operating profit growth | -122.9% | – | – |
| Net profit growth | -100.0% | – | – |
| EPS growth | -99.2% | -783.3% | – |
| OPM % | -5.0% | -4.0% | 3.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Valiant Laboratories.
Get Free AI Stock Analysis FREE →Latest News
-
Valiant Laboratories shareholders approve director re-appointments and RPTs - scanx.trade
-
Valiant Laboratories Limited Announces Evaluation of Restructuring Options Including Potential Amalgamation, Merger, and Demerger - scanx.trade
-
Valiant Laboratories Limited Announces Evaluation of Restructuring Options Including Potential Amalgamation, Merger, and Demerger - scanx.trade
-
Valiant Laboratories consolidated net profit rises 151.43% in the March 2026 quarter - Business Standard
-
Valiant Laboratories Reappoints Internal and Cost Auditors for FY 2026-27 - scanx.trade
-
Valiant Laboratories Reappoints Internal and Cost Auditors for FY 2026-27 - scanx.trade
Frequently Asked Questions
What is the share price of Valiant Laboratories today?
Valiant Laboratories shares were last quoted at ₹119.90 (+0.1% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Valiant Laboratories?
Valiant Laboratories has a price-to-earnings (P/E) ratio of 42.37 and a price-to-book (P/B) ratio of 2.05. The industry P/E is 53.33.
What is the 52-week high and low of Valiant Laboratories?
The 52-week high of Valiant Laboratories is ₹131.00 and the 52-week low is ₹50.00.
What is the market cap of Valiant Laboratories?
The market capitalisation of Valiant Laboratories is about ₹678.85 crore.
How did Valiant Laboratories perform in its latest quarterly results?
In the latest quarter (Jun 2026), Valiant Laboratories reported sales of ₹115.00 crore (+144.7%) and net profit of ₹21.00 crore (+950.0%), compared with the same quarter last year.
Is Valiant Laboratories a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Valiant Laboratories has a 3-year ROE of -1.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Valiant Laboratories?
Promoters hold about 74.94% of Valiant Laboratories.
Which sector does Valiant Laboratories belong to?
Valiant Laboratories belongs to the Pharmaceuticals & Drugs sector.